Zobrazeno 1 - 10
of 162
pro vyhledávání: '"M. Iskedjian"'
Publikováno v:
JCO Global Oncology
PURPOSE Health utilities (HUs) are quantitative measures of quality of life that are used to derive outcomes such as quality-adjusted life years in cost-effectiveness analyses. In the Kingdom of Saudi Arabia, there are no HUs for cancer. This study a
Autor:
Ahmed Al-Jedai, Ali M. Alhammad, Afshan A. Ali, M. Iskedjian, Fatma Maraiki, Ibrahim A. Aljuffali, Shouki Bazarbashi, Edward B. De Vol
Publikováno v:
PharmacoEconomics Open
Background No willingness-to-pay (WTP) per quality-adjusted life-year (QALY) value exists for the Kingdom of Saudi Arabia (KSA). Objective The primary objective of this study was to determine the WTP for a QALY in the KSA. Methods Adult citizens of t
Publikováno v:
Current Medical Research and Opinion. 26:2599-2606
This study presents previously unpublished point and cumulative incidence rates and relative risks (RRs) for comparing a partially hydrolysed 100% whey-based infant formula, NAN-HA * (PHF-W) to extensively hydrolysed whey- (EHF-Whey) or casein-based
Publikováno v:
Value in Health. 15(7)
Autor:
Jacques LeLorier, Amiran Gafni, J.H. Walker, B. Farah, M. Iskedjian, A. McLean, J. Berbari, J.A. Watson
Publikováno v:
Value in Health. 15(4)
Autor:
Ralf G. Heine, Jörg Spieldenner, John Sinn, Mimi L.K. Tang, Susan L. Prescott, John C Su, M. Iskedjian, Peter K. Smith
Publikováno v:
Journal of medical economics. 15(6)
OBJECTIVE: To perform an economic evaluation of a specific brand of partially hydrolyzed infant formula (PHF-W) in the prevention of atopic dermatitis (AD) among Australian infants. METHODS: A cost-effectiveness analysis was undertaken from the persp
Autor:
Hania Szajewska, Andrea von Berg, Christophe Dupont, Santiago Nevot Falcó, M. Iskedjian, Dominique Charles Belli, Ferdinand Haschke, Jörg Spieldenner
Publikováno v:
Annals of Nutrition and Metabolism, Vol. 59 Suppl 1 (2011) pp. 44-52
Clinical trials have demonstrated that the risk of developing atopic dermatitis is reduced when using hydrolysed formulas to feed infants with a documented risk of atopy (i.e. an affected parent and/or sibling)when breastfeeding is not practised. How
Publikováno v:
Journal of Medical Economics, Vol. 15, No 2 (2012) pp. 378-93
A pharmacoeconomic analysis was undertaken to determine costs, consequences, and cost-effectiveness of a partially hydrolyzed 100% whey-based infant formula, NAN-HA®, manufactured by Nestlé S.A, Switzerland (PHF-W), branded under BEBA HA® in Switz
Publikováno v:
Journal of medical economics. 15(2)
The objective of this study was to obtain utilities, or preference-based quality-of-life values, from the Canadian general public, for potential health states experienced by immune thrombocytopenia (ITP) patients receiving either romiplostim (a new t
Publikováno v:
Value in Health. 14(3)